AQR Capital Management
ALLO icon

AQR Capital Management’s Allogene Therapeutics ALLO Stock Holding History

AQR Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.06M Buy
2,484,780
+1,055,533
+74% +$2.12M ﹤0.01% 1626
2025
Q4 		$1.96M Sell
1,429,247
-424,307
-23% -$560K ﹤0.01% 2138
2025
Q3 		$2.3M Buy
1,853,554
+1,772,930
+2,199% +$2.11M ﹤0.01% 1898
2025
Q2 		$91.1K Buy
80,624
+22,401
+38% +$29.8K ﹤0.01% 3196
2025
Q1 		$85K Buy
+58,223
New +$110K ﹤0.01% 3039
2024
Q4 		– Sell
-33,589
Closed -$94K – 2865
2024
Q3 		$94K Buy
33,589
+6,302
+23% +$16.8K ﹤0.01% 2661
2024
Q2 		$63.6K Buy
+27,287
New +$80.5K ﹤0.01% 2530
2022
Q2 		– Sell
-73,717
Closed -$672K – 2175
2022
Q1 		$672K Buy
73,717
+44,832
+155% +$467K ﹤0.01% 1702
2021
Q4 		$431K Buy
28,885
+8,591
+42% +$152K ﹤0.01% 1869
2021
Q3 		$522K Sell
20,294
-16,423
-45% -$390K ﹤0.01% 1852
2021
Q2 		$958K Buy
+36,717
New +$1.05M ﹤0.01% 1611
2020
Q4 		– Sell
-8,576
Closed -$323K – 2179
2020
Q3 		$323K Buy
+8,576
New +$323K ﹤0.01% 1887

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management's ALLO Position: Q1 2026 in Review

AQR Capital Management increased its Allogene Therapeutics (ALLO) stake by 74% in Q1 2026, buying an estimated $2.12M and bringing the position to 2,484,780 shares worth $6.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1626.

AQR Capital Management first reported a position in ALLO in Q3 2020 and has held it in 12 quarters since. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • AQR Capital Management held 2,484,780 shares of Allogene Therapeutics worth $6.06M as of Q1 2026.
  • AQR Capital Management bought 1,055,533 Allogene Therapeutics shares in Q1 2026, an estimated $2.12M.
  • Allogene Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1626 holding.
  • AQR Capital Management first reported a position in Allogene Therapeutics in Q3 2020 and has held it in 12 quarters since.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.